GSK tops Access to Medicine Index, to invest £100M for initiatives in low income countries

The article leads with the number one ranking for GSK and gives an overview of the other top rankings, giving direct links to each mentioned company's stock.

Focus is given to the fact that, for the first time, all 20 companies in scope have access-to-medicine strategies, that there is evidence of increased access and strengthened delivery, and that more companies are engaging in voluntary licensing, making their products available for generic manufacture.

James Hazel, Research Programme Manager for the Access to Medicine Index is quoted, noting that improvements still overlook low-income countries.

Read the article on the Seeking Alpha website.